mayo clinic diet for glp 1 Healthy weight loss when GLP-1s are not an option What's New in 2025 |
Description
One of the most significant breakthroughs in MASLD and MASH targeted therapies is Resmetirom, an Food and Drug Administration (FDA)-approved agent for adults with noncirrhotic MASH with moderate to advanced fibrosis in conjunction to lifestyle therapy
Those questions have answers - they just require you to ask them before enrolling, not after
They typically subside as your body adjusts to the medication, though they may temporarily return if your provider increases your dosage
Pharmacol Ther 2021;227:107872
For employers, this results in pharmacy spending without better outcomes
